...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug news & perspectives >Are there any realistic chances to develop new drugs for asthma?
【24h】

Are there any realistic chances to develop new drugs for asthma?

机译：开发哮喘新药是否有现实的机会？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Asthma bronchiale, an inflammatory airway disease, imposes a significant health care problem worldwide. It is characterized by three critical phenotypic traits: intermittent and reversible bronchoconstriction, bronchial hyperresponsiveness and airway inflammation. Conventional therapy basically consists of beta(2)-adrenoceptor agonists in combination with glucocorticoids. Nevertheless, there is an urgent need for novel therapies, both for patients with uncontrollable disease symptoms and for those suffering from glucocorticoid-insensitive asthma. Monotherapy seems to be relatively ineffective against this complex and multifaceted disease, which is evident by the variety of disappointing treatment strategies. Thus, we should instead concentrate on multiple target strategies, such as novel and more potent glucocorticoids or phosphodiesterase type 4 (PDE4) inhibitors with isozyme selectivity. In addition, an examination of the application method should not be neglected, with emphasis on inhalative approaches. To summarize, research into asthma's pathophysiology is of critical importance, concentrating on human-relevant targets and conducting preliminary studies. With these imperatives in mind, we can hope to better manage this multifactor disease in the near future.
机译：哮喘性支气管哮喘是一种炎症性气道疾病，在全球范围内都引发了重大的医疗保健问题。它具有三个关键的表型特征：间歇性和可逆性支气管收缩，支气管高反应性和气道炎症。常规疗法主要由β（2）-肾上腺素受体激动剂与糖皮质激素结合而成。尽管如此，迫切需要新颖的疗法，无论是对于患有无法控制的疾病症状的患者，还是患有糖皮质激素不敏感的哮喘患者。单一疗法似乎对这种复杂和多方面的疾病相对无效，这在各种令人失望的治疗策略中很明显。因此，我们应该专注于多种目标策略，例如具有同工酶选择性的新型和更有效的糖皮质激素或4型磷酸二酯酶（PDE4）抑制剂。此外，不应忽略对应用方法的检查，而应重点考虑吸入方法。总而言之，对哮喘的病理生理学的研究至关重要，其重点是与人类有关的靶标并进行初步研究。考虑到这些必要性，我们可以希望在不久的将来更好地管理这种多因素疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号